Single-Dose Liposomal Amphotericin B Treatment for Cryptococcal Meningitis. 2022

Joseph N Jarvis, and David S Lawrence, and David B Meya, and Enock Kagimu, and John Kasibante, and Edward Mpoza, and Morris K Rutakingirwa, and Kenneth Ssebambulidde, and Lillian Tugume, and Joshua Rhein, and David R Boulware, and Henry C Mwandumba, and Melanie Moyo, and Henry Mzinganjira, and Cecilia Kanyama, and Mina C Hosseinipour, and Chimwemwe Chawinga, and Graeme Meintjes, and Charlotte Schutz, and Kyla Comins, and Achita Singh, and Conrad Muzoora, and Samuel Jjunju, and Edwin Nuwagira, and Mosepele Mosepele, and Tshepo Leeme, and Keatlaretse Siamisang, and Chiratidzo E Ndhlovu, and Admire Hlupeni, and Constantine Mutata, and Erik van Widenfelt, and Tao Chen, and Duolao Wang, and William Hope, and Timothée Boyer-Chammard, and Angela Loyse, and Síle F Molloy, and Nabila Youssouf, and Olivier Lortholary, and David G Lalloo, and Shabbar Jaffar, and Thomas S Harrison, and
From the Department of Clinical Research, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine (J.N.J., D.S.L., N.Y.), the Institute for Infection and Immunity, St. George's University London (A.L., S.F.M., T.S.H.), and the Clinical Academic Group in Infection and Immunity, St. George's University Hospitals NHS Foundation Trust (T.S.H.), London, Liverpool School of Tropical Medicine (H.C.M., E.W., D.W., D.G.L., S. Jaffar) and the Department of Public Health, Policy, and Systems, Institute of Population Health (T.C.), and the Department of Pharmacology and Therapeutics, Institute of Systems, Molecular, and Integrative Biology (W.H.), University of Liverpool, Liverpool, and the Medical Research Council Centre for Medical Mycology, University of Exeter, Exeter (T.S.H.) - all in the United Kingdom; the Botswana-Harvard AIDS Institute Partnership (J.N.J., D.S.L., M. Mosepele, T.L., K. Siamisang, N.Y.), the Departments of Internal Medicine (M. Mosepele) and Family Medicine and Public Health (K. Siamisang), University of Botswana, and the Department of Health Services Management, Ministry of Health and Wellness (K. Siamisang) - all in Gaborone, Botswana; the Infectious Diseases Institute, College of Health Sciences (D.B.M., E.K., J.K., E.M., M.K.R., K. Ssebambulidde, L.T., J.R., D.R.B., S. Jjunju, E.N.), and the Department of Medicine, School of Medicine (D.B.M.), Makerere University, Kampala, and Mbarara University of Science and Technology, Mbarara (C. Muzoora, E.N.) - both in Uganda; the University of Minnesota, Minneapolis (D.B.M., J.R., D.R.B.); the Malawi-Liverpool-Wellcome Trust Clinical Research Programme (H.C.M., M. Moyo, H.M., D.G.L.) and the Department of Medicine, Kamuzu University of Health Sciences (H.C.M., M. Moyo), Blantyre, and the Lilongwe Medical Relief Fund Trust (University of North Carolina-Malawi Project), Lilongwe (C.K., M.C.H., C.C.) - all in Malawi; the Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill (M.C.H.); the Wellcome Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine (G.M., C.S., K.C., A.S.), and the Department of Medicine (G.M., C.S., K.C.), University of Cape Town, and the Department of Radiology, Groote Schuur Hospital (A.S.) - both in Cape Town, South Africa; the Internal Medicine Unit, Faculty of Medicine and Health Sciences, University of Zimbabwe, Harare (C.E.N., A.H., C. Mutata); Institut Pasteur, National Center for Scientific Research, Molecular Mycology Unit and National Reference Center for Invasive Mycoses and Antifungals, Unités Mixtes de Recherche 2000, and Université de Paris, Necker Pasteur Center for Infectious Diseases and Tropical Medicine, Hôpital Necker Enfants Malades, Assistance Publique-Hôpitaux de Paris, Institut Hospitalo-Universitaire Imagine - both in Paris (T.B.-C., O.L.).

Cryptococcal meningitis is a leading cause of human immunodeficiency virus (HIV)-related death in sub-Saharan Africa. Whether a treatment regimen that includes a single high dose of liposomal amphotericin B would be efficacious is not known. In this phase 3 randomized, controlled, noninferiority trial conducted in five African countries, we assigned HIV-positive adults with cryptococcal meningitis in a 1:1 ratio to receive either a single high dose of liposomal amphotericin B (10 mg per kilogram of body weight) on day 1 plus 14 days of flucytosine (100 mg per kilogram per day) and fluconazole (1200 mg per day) or the current World Health Organization-recommended treatment, which includes amphotericin B deoxycholate (1 mg per kilogram per day) plus flucytosine (100 mg per kilogram per day) for 7 days, followed by fluconazole (1200 mg per day) for 7 days (control). The primary end point was death from any cause at 10 weeks; the trial was powered to show noninferiority at a 10-percentage-point margin. A total of 844 participants underwent randomization; 814 were included in the intention-to-treat population. At 10 weeks, deaths were reported in 101 participants (24.8%; 95% confidence interval [CI], 20.7 to 29.3) in the liposomal amphotericin B group and 117 (28.7%; 95% CI, 24.4 to 33.4) in the control group (difference, -3.9 percentage points); the upper boundary of the one-sided 95% confidence interval was 1.2 percentage points (within the noninferiority margin; P<0.001 for noninferiority). Fungal clearance from cerebrospinal fluid was -0.40 log10 colony-forming units (CFU) per milliliter per day in the liposomal amphotericin B group and -0.42 log10 CFU per milliliter per day in the control group. Fewer participants had grade 3 or 4 adverse events in the liposomal amphotericin B group than in the control group (50.0% vs. 62.3%). Single-dose liposomal amphotericin B combined with flucytosine and fluconazole was noninferior to the WHO-recommended treatment for HIV-associated cryptococcal meningitis and was associated with fewer adverse events. (Funded by the European and Developing Countries Clinical Trials Partnership and others; Ambition ISRCTN number, ISRCTN72509687.).

UI MeSH Term Description Entries
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005437 Flucytosine A fluorinated cytosine analog that is used as an antifungal agent. 5-Fluorocytosine,Alcobon,Ancobon,Ancotil
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000666 Amphotericin B Macrolide antifungal antibiotic produced by Streptomyces nodosus obtained from soil of the Orinoco river region of Venezuela. Amphocil,Amphotericin,Amphotericin B Cholesterol Dispersion,Amphotericin B Colloidal Dispersion,Fungizone
D000935 Antifungal Agents Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues. Anti-Fungal Agents,Antifungal Agent,Fungicides, Therapeutic,Antibiotics, Antifungal,Therapeutic Fungicides,Agent, Antifungal,Anti Fungal Agents,Antifungal Antibiotics
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D015725 Fluconazole Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS. Apo-Fluconazole,Béagyne,Diflucan,Fluc Hexal,FlucoLich,Flucobeta,Fluconazol AL,Fluconazol AbZ,Fluconazol Stada,Fluconazol von ct,Fluconazol-Isis,Fluconazol-ratiopharm,Flunazul,Fungata,Lavisa,Loitin,Neofomiral,Oxifungol,Solacap,Triflucan,UK-49858,Zonal,Apo Fluconazole,Fluconazol Isis,Fluconazol ratiopharm,UK 49858,UK49858
D016919 Meningitis, Cryptococcal Meningeal inflammation produced by CRYPTOCOCCUS NEOFORMANS, an encapsulated yeast that tends to infect individuals with ACQUIRED IMMUNODEFICIENCY SYNDROME and other immunocompromised states. The organism enters the body through the respiratory tract, but symptomatic infections are usually limited to the lungs and nervous system. The organism may also produce parenchymal brain lesions (torulomas). Clinically, the course is subacute and may feature HEADACHE; NAUSEA; PHOTOPHOBIA; focal neurologic deficits; SEIZURES; cranial neuropathies; and HYDROCEPHALUS. (From Adams et al., Principles of Neurology, 6th ed, pp721-2) Cryptococcal Meningitis,Granulomous Cerebral Cryptococcosis,Toruloma,Cerebral Cryptococcosis,Cerebral Cryptococcoses,Cerebral Cryptococcoses, Granulomous,Cerebral Cryptococcosis, Granulomous,Cryptococcal Meningitides,Cryptococcoses, Cerebral,Cryptococcoses, Granulomous Cerebral,Cryptococcosis, Cerebral,Cryptococcosis, Granulomous Cerebral,Granulomous Cerebral Cryptococcoses,Meningitides, Cryptococcal,Torulomas
D017088 AIDS-Related Opportunistic Infections Opportunistic infections found in patients who test positive for human immunodeficiency virus (HIV). The most common include PNEUMOCYSTIS PNEUMONIA, Kaposi's sarcoma, cryptosporidiosis, herpes simplex, toxoplasmosis, cryptococcosis, and infections with Mycobacterium avium complex, Microsporidium, and Cytomegalovirus. HIV-Related Opportunistic Infections,Opportunistic Infections, AIDS-Related,Opportunistic Infections, HIV-Related,AIDS Related Opportunistic Infections,AIDS-Related Opportunistic Infection,HIV Related Opportunistic Infections,HIV-Related Opportunistic Infection,Infection, HIV-Related Opportunistic,Infections, HIV-Related Opportunistic,Opportunistic Infection, AIDS-Related,Opportunistic Infection, HIV-Related,Opportunistic Infections, AIDS Related,Opportunistic Infections, HIV Related

Related Publications

Joseph N Jarvis, and David S Lawrence, and David B Meya, and Enock Kagimu, and John Kasibante, and Edward Mpoza, and Morris K Rutakingirwa, and Kenneth Ssebambulidde, and Lillian Tugume, and Joshua Rhein, and David R Boulware, and Henry C Mwandumba, and Melanie Moyo, and Henry Mzinganjira, and Cecilia Kanyama, and Mina C Hosseinipour, and Chimwemwe Chawinga, and Graeme Meintjes, and Charlotte Schutz, and Kyla Comins, and Achita Singh, and Conrad Muzoora, and Samuel Jjunju, and Edwin Nuwagira, and Mosepele Mosepele, and Tshepo Leeme, and Keatlaretse Siamisang, and Chiratidzo E Ndhlovu, and Admire Hlupeni, and Constantine Mutata, and Erik van Widenfelt, and Tao Chen, and Duolao Wang, and William Hope, and Timothée Boyer-Chammard, and Angela Loyse, and Síle F Molloy, and Nabila Youssouf, and Olivier Lortholary, and David G Lalloo, and Shabbar Jaffar, and Thomas S Harrison, and
July 2022, The New England journal of medicine,
Joseph N Jarvis, and David S Lawrence, and David B Meya, and Enock Kagimu, and John Kasibante, and Edward Mpoza, and Morris K Rutakingirwa, and Kenneth Ssebambulidde, and Lillian Tugume, and Joshua Rhein, and David R Boulware, and Henry C Mwandumba, and Melanie Moyo, and Henry Mzinganjira, and Cecilia Kanyama, and Mina C Hosseinipour, and Chimwemwe Chawinga, and Graeme Meintjes, and Charlotte Schutz, and Kyla Comins, and Achita Singh, and Conrad Muzoora, and Samuel Jjunju, and Edwin Nuwagira, and Mosepele Mosepele, and Tshepo Leeme, and Keatlaretse Siamisang, and Chiratidzo E Ndhlovu, and Admire Hlupeni, and Constantine Mutata, and Erik van Widenfelt, and Tao Chen, and Duolao Wang, and William Hope, and Timothée Boyer-Chammard, and Angela Loyse, and Síle F Molloy, and Nabila Youssouf, and Olivier Lortholary, and David G Lalloo, and Shabbar Jaffar, and Thomas S Harrison, and
December 2022, The Lancet. Global health,
Joseph N Jarvis, and David S Lawrence, and David B Meya, and Enock Kagimu, and John Kasibante, and Edward Mpoza, and Morris K Rutakingirwa, and Kenneth Ssebambulidde, and Lillian Tugume, and Joshua Rhein, and David R Boulware, and Henry C Mwandumba, and Melanie Moyo, and Henry Mzinganjira, and Cecilia Kanyama, and Mina C Hosseinipour, and Chimwemwe Chawinga, and Graeme Meintjes, and Charlotte Schutz, and Kyla Comins, and Achita Singh, and Conrad Muzoora, and Samuel Jjunju, and Edwin Nuwagira, and Mosepele Mosepele, and Tshepo Leeme, and Keatlaretse Siamisang, and Chiratidzo E Ndhlovu, and Admire Hlupeni, and Constantine Mutata, and Erik van Widenfelt, and Tao Chen, and Duolao Wang, and William Hope, and Timothée Boyer-Chammard, and Angela Loyse, and Síle F Molloy, and Nabila Youssouf, and Olivier Lortholary, and David G Lalloo, and Shabbar Jaffar, and Thomas S Harrison, and
September 1962, Canadian Medical Association journal,
Joseph N Jarvis, and David S Lawrence, and David B Meya, and Enock Kagimu, and John Kasibante, and Edward Mpoza, and Morris K Rutakingirwa, and Kenneth Ssebambulidde, and Lillian Tugume, and Joshua Rhein, and David R Boulware, and Henry C Mwandumba, and Melanie Moyo, and Henry Mzinganjira, and Cecilia Kanyama, and Mina C Hosseinipour, and Chimwemwe Chawinga, and Graeme Meintjes, and Charlotte Schutz, and Kyla Comins, and Achita Singh, and Conrad Muzoora, and Samuel Jjunju, and Edwin Nuwagira, and Mosepele Mosepele, and Tshepo Leeme, and Keatlaretse Siamisang, and Chiratidzo E Ndhlovu, and Admire Hlupeni, and Constantine Mutata, and Erik van Widenfelt, and Tao Chen, and Duolao Wang, and William Hope, and Timothée Boyer-Chammard, and Angela Loyse, and Síle F Molloy, and Nabila Youssouf, and Olivier Lortholary, and David G Lalloo, and Shabbar Jaffar, and Thomas S Harrison, and
February 1991, AIDS (London, England),
Joseph N Jarvis, and David S Lawrence, and David B Meya, and Enock Kagimu, and John Kasibante, and Edward Mpoza, and Morris K Rutakingirwa, and Kenneth Ssebambulidde, and Lillian Tugume, and Joshua Rhein, and David R Boulware, and Henry C Mwandumba, and Melanie Moyo, and Henry Mzinganjira, and Cecilia Kanyama, and Mina C Hosseinipour, and Chimwemwe Chawinga, and Graeme Meintjes, and Charlotte Schutz, and Kyla Comins, and Achita Singh, and Conrad Muzoora, and Samuel Jjunju, and Edwin Nuwagira, and Mosepele Mosepele, and Tshepo Leeme, and Keatlaretse Siamisang, and Chiratidzo E Ndhlovu, and Admire Hlupeni, and Constantine Mutata, and Erik van Widenfelt, and Tao Chen, and Duolao Wang, and William Hope, and Timothée Boyer-Chammard, and Angela Loyse, and Síle F Molloy, and Nabila Youssouf, and Olivier Lortholary, and David G Lalloo, and Shabbar Jaffar, and Thomas S Harrison, and
January 2012, Chinese medical journal,
Joseph N Jarvis, and David S Lawrence, and David B Meya, and Enock Kagimu, and John Kasibante, and Edward Mpoza, and Morris K Rutakingirwa, and Kenneth Ssebambulidde, and Lillian Tugume, and Joshua Rhein, and David R Boulware, and Henry C Mwandumba, and Melanie Moyo, and Henry Mzinganjira, and Cecilia Kanyama, and Mina C Hosseinipour, and Chimwemwe Chawinga, and Graeme Meintjes, and Charlotte Schutz, and Kyla Comins, and Achita Singh, and Conrad Muzoora, and Samuel Jjunju, and Edwin Nuwagira, and Mosepele Mosepele, and Tshepo Leeme, and Keatlaretse Siamisang, and Chiratidzo E Ndhlovu, and Admire Hlupeni, and Constantine Mutata, and Erik van Widenfelt, and Tao Chen, and Duolao Wang, and William Hope, and Timothée Boyer-Chammard, and Angela Loyse, and Síle F Molloy, and Nabila Youssouf, and Olivier Lortholary, and David G Lalloo, and Shabbar Jaffar, and Thomas S Harrison, and
April 2002, The Journal of the Association of Physicians of India,
Joseph N Jarvis, and David S Lawrence, and David B Meya, and Enock Kagimu, and John Kasibante, and Edward Mpoza, and Morris K Rutakingirwa, and Kenneth Ssebambulidde, and Lillian Tugume, and Joshua Rhein, and David R Boulware, and Henry C Mwandumba, and Melanie Moyo, and Henry Mzinganjira, and Cecilia Kanyama, and Mina C Hosseinipour, and Chimwemwe Chawinga, and Graeme Meintjes, and Charlotte Schutz, and Kyla Comins, and Achita Singh, and Conrad Muzoora, and Samuel Jjunju, and Edwin Nuwagira, and Mosepele Mosepele, and Tshepo Leeme, and Keatlaretse Siamisang, and Chiratidzo E Ndhlovu, and Admire Hlupeni, and Constantine Mutata, and Erik van Widenfelt, and Tao Chen, and Duolao Wang, and William Hope, and Timothée Boyer-Chammard, and Angela Loyse, and Síle F Molloy, and Nabila Youssouf, and Olivier Lortholary, and David G Lalloo, and Shabbar Jaffar, and Thomas S Harrison, and
October 1991, The Journal of antimicrobial chemotherapy,
Joseph N Jarvis, and David S Lawrence, and David B Meya, and Enock Kagimu, and John Kasibante, and Edward Mpoza, and Morris K Rutakingirwa, and Kenneth Ssebambulidde, and Lillian Tugume, and Joshua Rhein, and David R Boulware, and Henry C Mwandumba, and Melanie Moyo, and Henry Mzinganjira, and Cecilia Kanyama, and Mina C Hosseinipour, and Chimwemwe Chawinga, and Graeme Meintjes, and Charlotte Schutz, and Kyla Comins, and Achita Singh, and Conrad Muzoora, and Samuel Jjunju, and Edwin Nuwagira, and Mosepele Mosepele, and Tshepo Leeme, and Keatlaretse Siamisang, and Chiratidzo E Ndhlovu, and Admire Hlupeni, and Constantine Mutata, and Erik van Widenfelt, and Tao Chen, and Duolao Wang, and William Hope, and Timothée Boyer-Chammard, and Angela Loyse, and Síle F Molloy, and Nabila Youssouf, and Olivier Lortholary, and David G Lalloo, and Shabbar Jaffar, and Thomas S Harrison, and
July 2016, Infectious diseases (London, England),
Joseph N Jarvis, and David S Lawrence, and David B Meya, and Enock Kagimu, and John Kasibante, and Edward Mpoza, and Morris K Rutakingirwa, and Kenneth Ssebambulidde, and Lillian Tugume, and Joshua Rhein, and David R Boulware, and Henry C Mwandumba, and Melanie Moyo, and Henry Mzinganjira, and Cecilia Kanyama, and Mina C Hosseinipour, and Chimwemwe Chawinga, and Graeme Meintjes, and Charlotte Schutz, and Kyla Comins, and Achita Singh, and Conrad Muzoora, and Samuel Jjunju, and Edwin Nuwagira, and Mosepele Mosepele, and Tshepo Leeme, and Keatlaretse Siamisang, and Chiratidzo E Ndhlovu, and Admire Hlupeni, and Constantine Mutata, and Erik van Widenfelt, and Tao Chen, and Duolao Wang, and William Hope, and Timothée Boyer-Chammard, and Angela Loyse, and Síle F Molloy, and Nabila Youssouf, and Olivier Lortholary, and David G Lalloo, and Shabbar Jaffar, and Thomas S Harrison, and
April 2014, The Lancet. Global health,
Joseph N Jarvis, and David S Lawrence, and David B Meya, and Enock Kagimu, and John Kasibante, and Edward Mpoza, and Morris K Rutakingirwa, and Kenneth Ssebambulidde, and Lillian Tugume, and Joshua Rhein, and David R Boulware, and Henry C Mwandumba, and Melanie Moyo, and Henry Mzinganjira, and Cecilia Kanyama, and Mina C Hosseinipour, and Chimwemwe Chawinga, and Graeme Meintjes, and Charlotte Schutz, and Kyla Comins, and Achita Singh, and Conrad Muzoora, and Samuel Jjunju, and Edwin Nuwagira, and Mosepele Mosepele, and Tshepo Leeme, and Keatlaretse Siamisang, and Chiratidzo E Ndhlovu, and Admire Hlupeni, and Constantine Mutata, and Erik van Widenfelt, and Tao Chen, and Duolao Wang, and William Hope, and Timothée Boyer-Chammard, and Angela Loyse, and Síle F Molloy, and Nabila Youssouf, and Olivier Lortholary, and David G Lalloo, and Shabbar Jaffar, and Thomas S Harrison, and
June 1959, Nordisk medicin,
Copied contents to your clipboard!